Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Health Canada gives priority review status to ProMetic's NDS for Ryplazim

Oct. 20, 2017

No Comments

Acticor Biotech reaches agreement on phase I study of ACT-107

Oct. 18, 2017

No Comments

Bayer submits marketing authorization application for BAY-94-9027 in Japan

Oct. 18, 2017

No Comments

FDA accepts ProMetic's BLA for Ryplazim

Oct. 16, 2017

No Comments

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Oct. 6, 2017

No Comments

FDA accepts IND for gene-edited cell therapy for beta-thalassemia

Oct. 5, 2017

No Comments

FDA not to hold committee meeting to discuss Rigel's NDA for fostamatinib

Oct. 3, 2017

No Comments

Ablynx reports phase III results for caplacizumab in aTTP

Oct. 2, 2017

No Comments

Ruconest provides clinically meaningful relief of symptons in phase II study

Oct. 2, 2017

No Comments

Alnylam Pharmaceuticals begins phase II study of cemdisiran in aHUS

Sep. 28, 2017

No Comments

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Hematologic
RSS

Health Canada gives priority review status to ProMetic's NDS for Ryplazim

Acticor Biotech reaches agreement on phase I study of ACT-107

Bayer submits marketing authorization application for BAY-94-9027 in Japan

FDA accepts ProMetic's BLA for Ryplazim

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

FDA accepts IND for gene-edited cell therapy for beta-thalassemia

FDA not to hold committee meeting to discuss Rigel's NDA for fostamatinib

Ablynx reports phase III results for caplacizumab in aTTP

Ruconest provides clinically meaningful relief of symptons in phase II study

Alnylam Pharmaceuticals begins phase II study of cemdisiran in aHUS

Today's news in brief

Today's news in brief

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

Australia’s Celosia heads toward clinic with gene therapy for ALS

Sangamo stock plunges as Pfizer leaves hemophilia partnership

Hematologic RSS

Hematologic
RSS